American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 | Latest News RSS Feed

American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 - Latest News
Sodium-Glucose Cotransporter 2 Inhibitors: An Overview
The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology ... per the AACE/ACE guidelines, SGLT2 inhibitors are preferred to alternative antidiabetic ...
read more
Add your link right here
Add your story here to improve SEO, search ranking and drive traffic to your website. Your link will be permanently featured right on this page. To add a link on diferent page, just visit the page you want to show your link and click "Add your link right here". You can use search form below to find the page.
read more
Best Treatments for Type 2 Diabetes
Type 2 diabetes is one of the most serious ... Medical experts don't all agree exactly how often adults should have a diabetes test. The American Diabetes Association advises that everyone aged ...
read more
Is One SGLT2 (Or GLP-1) Just Like Another for Cardiac Benefit?
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
read more
Looking for other news?
Sulfonylurea Use and the Risk of Hospital Readmission in Patients With Type 2 Diabetes
This study documented, using a nationally representative database from 1999 to 2010, 2.6 million patients with type 2 diabetes and with multiple hospitalizations. Patients treated with SU ...
read more
Top POEMs of 2019
American Family Physician's annual collection of the top 20 research studies for primary care addresses a variety of topics with the potential to change practice. A group of primary care ...
read more
VIVUS, Inc. (VVUS)
See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b ‑2 of the Exchange Act. (Check one): ...
read more